Bone-seeking (osteotropic) drug delivery systems (ODDS) represent an\r\ninteresting solution for targeting different types of drugs to the bones. In particular,\r\nanticancer and antibacterial agents could take advantage of such therapeutic strategy. We\r\nhave recently developed an innovative approach to this aim: a new osteotropic biomaterial\r\nwas prepared, based on the conjugation of a poly(lactide-co-glycolide) (PLGA) with the\r\nbisphosphonate drug alendronate (PLGA-ALE); its hemo- and cytocompatibility were\r\nverified. Starting with this copolymer, an osteotropic nanoparticle system (NP) was produced\r\nfor the targeted delivery of antineoplastic drugs to osteolytic bone metastases; in particular,\r\ndoxorubicin was tested as a model drug. The in vitro and in vivo results of the new ODDS\r\nare validated in this article. All the experimental data confirmed that the drug retained its\r\nactivity after loading in the PLGA-ALE NP; they can be thus considered a new promising\r\nstrategy for active targeting of drugs to bone tissues in different pathological situations.
Loading....